{
    "clinical_study": {
        "@rank": "15129", 
        "arm_group": [
            {
                "arm_group_label": "Creatine 10g", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects randomized to this study arm will receive 10g of daily creatine for 8 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects randomized to this study arm will receive daily placebo for 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for\n      eight weeks will be associated with significant increases in frontal lobe phosphocreatine\n      and beta-nucleoside triphosphate (\u03b2-NTP) concentrations.  A secondary hypothesis is that\n      decreased depressive symptoms measured with the Children's Depression Rating Scale-Revised\n      (CDRS-R) and Montgomery-Asberg Depression Rating Scale (MADRS) will be reciprocally\n      correlated with increased \u03b2-NTP concentrations."
        }, 
        "brief_title": "Placebo-Controlled Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder: a Magnetic Resonance Spectroscopy Study", 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "The current protocol seeks to expand upon the investigators previous work by opening\n      recruitment on a pilot study of creatine 10g daily vs. placebo as a treatment for female\n      adolescents with SSRI-resistant MDD.  The purpose of the pilot study is twofold: A) to\n      evaluate several aspects of the feasibility of creatine supplementation as a treatment for\n      this population; and B) to estimate the effect size of adjunctive creatine, to inform the\n      design and implementation of a potential future efficacy trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "MDD SUBJECTS\n\n        Inclusion Criteria:\n\n          1. Participants must be female.\n\n          2. Participants must be able to grant informed consent (age >18), or parent/guardian\n             permission plus participant assent (age <18).\n\n          3. Participants must meet DSM-IV criteria for Major Depressive Disorder (MDD), with\n             current mood state depressed for > 2 weeks.\n\n          4. Participants must be between the ages of 12 and 21.\n\n          5. Current CDRS-R raw score of > 40 or MADRS score >25; and CGI-S score >4.\n\n          6. Participants may be enrolled in individual and/or group psychotherapy, if it has been\n             ongoing for at least 8 weeks.\n\n          7. Participants must have been in treatment with an SSRI for at least 8 weeks, the last\n             4 of which were at a dosage of >20 mg per day of fluoxetine or its equivalent, e.g.\n             20 mg per day of paroxetine, 20 mg citalopram, 10 mg escitalopram, or 100 mg\n             sertraline.  If the participant attempted, but could not tolerate, a dose comparable\n             to 20 mg fluoxetine, they will be considered eligible.  (This definition of\n             \"Adolescent SSRI Resistant Depression\" is modified from the NIH-sponsored, $17\n             million TORDIA Randomized Controlled Trial\n             [http://clinicaltrials.gov/ct2/show/NCT00018902].\n\n        Exclusion Criteria:\n\n          1. Unstable co-morbid medical, neurological, or psychiatric disorder.\n\n          2. Current DSM-IV criteria for substance abuse or dependence (excepting\n             nicotine/cigarettes).\n\n          3. Clinically significant suicidal or homicidal risk.\n\n          4. Pre-existing renal disease.\n\n          5. Proteinuria on baseline urinalysis testing.\n\n          6. Pregnancy or breastfeeding.\n\n          7. Sexually active and unwilling to practice contraception during the study.\n\n          8. Contraindication to magnetic resonance imaging (e.g. ferromagnetic implant or\n             claustrophobia)\n\n          9. History of hypersensitivity to creatine.\n\n         10. History of a previous failed therapeutic trial of creatine.\n\n         11. Participants may be outpatients or inpatients, but incarcerated persons will be\n             excluded because this study is not approved for \"Research Involving Prisoners.\"\n\n        Study Withdrawal Criteria:\n\n          1. Withdrawal of parental permission, participant informed consent, or participant\n             assent.\n\n          2. Onset of a psychotic disorder or bipolar disorder.\n\n          3. Intolerable or clinically significant side effects to creatine.\n\n          4. Worsening depression, as demonstrated by an increase in CDRS-R or MADRS score >25%\n             from baseline.\n\n          5. Positive pregnancy test.\n\n          6. A significant change to the participant's medication or psychotherapy treatment from\n             the regimen reported at their baseline/screening visit (e.g. the SSRI is\n             discontinued).\n\n          7. Incarceration, as the study is not approved to conduct \"Research Involving\n             Prisoners.\"\n\n          8. If a clinically significant intracranial lesion is found by the Radiologist on a\n             participant's baseline brain scan, they will be withdrawn from the study and referred\n             for appropriate medical care.\n\n          9. The principal investigator retains the right to withdraw participants from the study\n             without their permission, in the event they are unwilling or unable to maintain\n             adherence to the research protocol.\n\n        HEALTHY COMPARISON SUBJECTS\n\n        Inclusion Criteria:\n\n          1. Participants must be able to grant informed consent (age >18), or parent/guardian\n             permission plus participant assent (age <18).\n\n          2. Participants must be female.\n\n          3. Participants must be between the ages of 12 and 21 years.\n\n          4. Participants must not meet DSM-IV-TR criteria for a current psychiatric illness or\n             substance use disorder.\n\n          5. Participants must have a CDRS-R score < 30.\n\n        Exclusion Criteria:\n\n          1. Unstable medical or neurological illness.\n\n          2. Clinically significant psychiatric or substance use disorder.\n\n          3. Pregnant subjects, due to the unknown effects of MRI/MRS scans on a fetus.  In\n             addition, women of childbearing potential who are unable or unwilling to practice\n             contraception during the study will be excluded.  Female participants who are of\n             childbearing potential must have a negative urine pregnancy test before the MRI/MRS\n             scan.\n\n          4. Participants with a contraindication to MRI/MRS scanning, such as a metallic implant.\n\n        Study Withdrawal Criteria:\n\n          1. Withdrawal of parental permission or participant assent.\n\n          2. Onset of a psychotic disorder or depression.\n\n          3. Positive pregnancy test.\n\n          4. A significant change to the participant's medication or psychotherapy treatment from\n             the regimen reported at their baseline/screening visit, unless directed by the\n             principal investigator."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "21 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134808", 
            "org_study_id": "00073442"
        }, 
        "intervention": [
            {
                "arm_group_label": "Creatine 10g", 
                "intervention_name": "Creatine", 
                "intervention_type": "Drug", 
                "other_name": "Creatine monohydrate"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Major Depressive Disorder", 
            "Creatine", 
            "Brain Chemistry", 
            "Magnetic Resonance Spectroscopy"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "contact": {
                "email": "lauren.forrest@utah.edu", 
                "last_name": "Lauren Forrest, BS", 
                "phone": "801-587-1506"
            }, 
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84108"
                }, 
                "name": "University of Utah"
            }, 
            "investigator": {
                "last_name": "Douglas Kondo, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "lauren.forrest@utah.edu", 
            "last_name": "Lauren Forrest, BS", 
            "phone": "801-587-1506"
        }, 
        "overall_contact_backup": {
            "email": "danielle.kuykendall@utah.edu", 
            "last_name": "Danielle Kuykendall, RN, MPH", 
            "phone": "801-450-2196"
        }, 
        "overall_official": {
            "affiliation": "University of Utah", 
            "last_name": "Douglas Kondo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "PCr will be measured through 31phosphorus magnetic resonance spectroscopy (31P-MRS). This type of brain imaging will be performed in a 3 Tesla (3T) magnetic resonance imaging (MRI) scanner.", 
                "measure": "Brain phosphocreatine (PCr) concentrations", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "\u03b2-NTP will be measured through 31phosphorus magnetic resonance spectroscopy (31P-MRS).  This type of brain imaging will be performed in a 3 Tesla (3T) magnetic resonance imaging (MRI) scanner.", 
                "measure": "Brain beta-nucleoside triphosphate (\u03b2-NTP) concentrations", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "reference": {
            "PMID": "21831448", 
            "citation": "Kondo DG, Sung YH, Hellem TL, Fiedler KK, Shi X, Jeong EK, Renshaw PF. Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. J Affect Disord. 2011 Dec;135(1-3):354-61. doi: 10.1016/j.jad.2011.07.010. Epub 2011 Aug 9."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134808"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Utah", 
            "investigator_full_name": "Perry Renshaw", 
            "investigator_title": "Professor of Psychiatry", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "The CDRS-R will be administered to understand the severity of depressive symptoms, and how these symptoms change throughout the course of the study.", 
            "measure": "Children's Depression Rating Scale-Revised (CDRS-R)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "University of Utah", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Perry Renshaw", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}